Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Other Operating Expenses (2016 - 2025)

Standard Biotools (LAB) has disclosed Other Operating Expenses for 16 consecutive years, with $13.3 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 138.96% to $13.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.1 million through Dec 2025, up 108.97% year-over-year, with the annual reading at $14.8 million for FY2025, 108.76% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $13.3 million at Standard Biotools, up from $43000.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $14.8 million in Q3 2021, with the low at -$57.7 million in Q2 2024.
  • Average Other Operating Expenses over 5 years is -$15.0 million, with a median of $157000.0 recorded in 2025.
  • The sharpest move saw Other Operating Expenses plummeted 1307.62% in 2023, then soared 138.96% in 2025.
  • Over 5 years, Other Operating Expenses stood at $14.8 million in 2021, then crashed by 68.79% to $4.6 million in 2022, then plummeted by 1293.95% to -$55.3 million in 2023, then skyrocketed by 38.41% to -$34.0 million in 2024, then skyrocketed by 138.96% to $13.3 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $13.3 million, $43000.0, and $271000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.